Indeed, the documented survival benefit of tebentafusp in HLA‐A*02:01–positive metastatic uveal melanoma and the ability of ADI‐PEG20 to generate citrulline and maintain the immune cell compartment provides an opportunity for further development of immunometabolic approaches for UM (Nathan et al., 2021; Werner et al., 2017). The gene discussed is HLA-A; the disease is uveal melanoma.